|
 |
|||||||||||
Course Description and New Features
Valvular heart diseases are “mystery killers.” Generally, they progress very slowly and almost imperceptibly, yet can cause sudden and unexpected death. They are among the most prominent causes of heart failure and premature cardiac death. It is estimated that more than 10 million Americans have some type of heart valve abnormality, and in approximately five million, the disease is moderate to severe. Three to four million will require surgery at some time in their lives. These numbers are increasing as the population matures, because heart valve diseases develop and progress with aging. Since other causes of relatively early death are diminishing, valve diseases are emerging as an important public health concern. Valves in the Heart of the Big Apple VII: Evaluation & Management of Valvular Heart Diseases 2012will provide the target audience — cardiologists, cardiothoracic surgeons, interventionalists, physicians, anesthesiologists, engineers, basic researchers and other health care professionals — with state-of-the-art lectures, symposia, and abstract and case presentations covering the spectrum of valve diseases. The program will provide the latest strategies for evaluation and management of patients with valvular heart disease. It will also provide the pathophysiological basis of outcomes, including most recent data concerning myocardial responses at the cellular and molecular levels, will be discussed to elucidate the foundation for future therapy. Valves in the Heart of the Big Apple VII will get to the core of major valvular heart disease issues.
New & Recently-Updated Features
|
 |
|||||||||||
